Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9

Journal of Clinical Lipidology
Jonathan B EdmistonMichael D Shapiro

Abstract

Clinical trials testing proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have demonstrated an unanticipated but significant lipoprotein (a) (Lp(a))-lowering effect, on the order of 25% to 30%. Although the 50% to 60% reduction in low-density lipoprotein (LDL)-cholesterol (LDL-C) achieved by PCSK9i is mediated through its effect on LDL receptor (LDLR) preservation, the mechanism for Lp(a) lowering is unknown. We sought to characterize the degree of concordance between LDL-C and Lp(a) lowering because of PCSK9i in a standard of care patient cohort. Participants were selected from our Center for Preventive Cardiology, an outpatient referral center in a tertiary academic medical center. Subjects were included in this study if they had (1) at least 1 measurement of LDL-C and Lp(a) before and after initiation of the PCSK9i; (2) baseline Lp(a) > 10 mg/dL; and (3) continued adherence to PCSK9i therapy. They were excluded if (1) they were undergoing LDL apheresis; (2) pre- or post-PCSK9i LDL-C or Lp(a) laboratory values were censored; or (3) subjects discontinued other lipid-modifying therapies. In total, 103 subjects were identified as taking a PCSK9i and 26 met all inclusion and exclusion criteria. Concordant response...Continue Reading

Citations

May 2, 2018·Current Opinion in Lipidology·Deepak Bhatnagar, Ahmad Shiraz
Sep 11, 2018·Current Opinion in Lipidology·Stéphane Ramin-MangataGilles Lambert
Oct 13, 2018·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Francesco SbranaTiziana Sampietro
Oct 28, 2018·Nature Reviews. Endocrinology·Robert M StoekenbroekG Kees Hovingh
Dec 28, 2018·Circulation·Michelle L O'DonoghueMarc S Sabatine
Jun 28, 2019·Current Opinion in Cardiology·Tahir Mahmood, Michael D Shapiro
Jan 25, 2020·Expert Opinion on Drug Discovery·Etienne KhouryDaniel Gaudet
May 24, 2020·European Journal of Preventive Cardiology·Evangelos Liberopoulos
May 12, 2018·Circulation Research·Michael D ShapiroSergio Fazio
Feb 23, 2020·Arteriosclerosis, Thrombosis, and Vascular Biology·Mikaël CroyalEstelle Nobécourt-Dupuy
Sep 14, 2020·The Korean Journal of Internal Medicine·Kyung Hoon Cho, Young Joon Hong
Mar 9, 2019·Current Atherosclerosis Reports·Željko Reiner
Feb 15, 2020·Journal of the American College of Cardiology·P Barton Duell, Sergio Fazio
Feb 22, 2021·European Journal of Preventive Cardiology·Evangelos Liberopoulos
May 1, 2020·American Journal of Preventive Cardiology·Bruce A WardenSergio Fazio
Sep 8, 2021·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Jennifer HardyRushab Choksi
Dec 11, 2019·Atherosclerosis. Supplements·Ulrich JuliusStefan R Bornstein

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.